Condition: Neovascular (Wet) Age-Related Macular Degeneration · Sponsor: Eyconis INC.
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
This description comes directly from the study's public registry record.
Kim Reed, OD, FAAO · 1-866-392-6647 · info@eyconis.com
Karen Chu, MS · 1-866-392-6647 · info@eyconis.com
Always discuss trial participation with your own doctor first.
| Beverly Hills, CA | Beverly Hills, California, United States | Recruiting |
| Wake Forest, NC | Wake Forest, North Carolina, United States | Recruiting |
| Erie, PA | Erie, Pennsylvania, United States | Recruiting |
| Bellaire, TX | Bellaire, Texas, United States | Recruiting |
| McAllen, TX | McAllen, Texas, United States | Recruiting |
| The Woodlands, TX | The Woodlands, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07587515